Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study "ARC"

Completed

Phase 4 Results N/A

Update History

4 Feb '15
A location was updated in Chicago.
New
The overall status was removed for Cook County Hospital.
30 Oct '13
The eligibility criteria were updated.
New
Inclusion Criteria: - Patients with non-valvular atrial fibrillation requiring electrical cardioversion o Atrial fibrillation of unknown duration Exclusion Criteria: - Patients requiring extended anticoagulation after cardioversion due to concomitant risk factors as defined by CHADS2 score ≥ 1 - Significant renal dysfunction (CrCl <15mL/min) - Significant hepatic dysfunction (Childs-Pugh Class B or C) - History of coagulopathy - Active bleeding - Hypersensitivity to Rivaroxaban - Concomitant use of anticoagulants - Concomitant use of potent CYP3A4/P-gp inhibitors or inducers - Interventions requiring interruption of therapy - Pregnancy - Age <18 y/o - History of GI Bleed
Old
Inclusion Criteria: - Patients with non-valvular atrial fibrillation requiring electrical cardioversion o Atrial fibrillation of unknown duration Exclusion Criteria: - Patients requiring extended anticoagulation after cardioversion due to concomitant risk factors as defined by CHADS2 score ≥ 1 - Significant renal dysfunction (CrCl <15mL/min) - Significant hepatic dysfunction (Childs-Pugh Class B or C) - History of coagulopathy - Active bleeding - Hypersensitivity to Rivaroxaban - Concomitant use of anticoagulants - Concomitant use of potent CYP3A4/P-gp inhibitors or inducers - Interventions requiring interruption of therapy - Pregnancy - Age <18 y/o